Abstract
Alzheimers disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid- β (Aβ) as plaques and in cerebral blood vessels. Numerous Aβ targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patients immune status, genetic background and their amyloid burden, as determined by imaging studies using Aβ specific labeling ligands. Preclinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Keywords: neurotoxicity, CNS neurons, RAGE-mediated transport, tau phosphorylation, Amyloid beta Deposition
Current Pharmaceutical Design
Title: Disease Modifying Approaches for Alzheimers Pathology
Volume: 13 Issue: 19
Author(s): Marcin Sadowski and Thomas Wisniewski
Affiliation:
Keywords: neurotoxicity, CNS neurons, RAGE-mediated transport, tau phosphorylation, Amyloid beta Deposition
Abstract: Alzheimers disease (AD) is the most common age-associated neurodegenerative disease in the world. The major neuropathological features of AD are synaptic loss, neuronal loss, neurofibrillary tangles and the deposition of amyloid- β (Aβ) as plaques and in cerebral blood vessels. Numerous Aβ targeting therapeutic approaches have been shown to prevent amyloid deposition and resulting in cognitive improvement in transgenic mouse models of AD. Some of these approaches are currently in early clinical trials. It remains to be seen if these approaches will be proven effective in patients. Future anti-AD therapies will likely be multi-modal and individually tailored depending on the patients immune status, genetic background and their amyloid burden, as determined by imaging studies using Aβ specific labeling ligands. Preclinical data suggests that it will be much more feasible to prevent AD related pathology, then to clear existing pathology, making early diagnosis critically important.
Export Options
About this article
Cite this article as:
Marcin Sadowski and Thomas Wisniewski , Disease Modifying Approaches for Alzheimers Pathology, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039788
DOI https://dx.doi.org/10.2174/138161207781039788 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Antiepileptic Drug-Induced Hypersensitivity Syndrome Reactions
Current Drug Safety Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Current Pharmaceutical Design FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Serum Adiponectin Levels in Patients with Familial Mediterranean Fever
Protein & Peptide Letters Leptin-Induced Endothelial Dysfunction: A Target for Therapeutic Interventions
Current Pharmaceutical Design Experimental Approaches Towards Allergic Asthma Therapy-Murine Asthma Models
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Cytokines in T Help Responses to Viruses
Current Immunology Reviews (Discontinued) Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Cellulitis-Like Sweet Syndrome Preceding Multiple Myeloma. A Case Report
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Vasculitis Following Influenza Vaccination: A Review of the Literature
Current Rheumatology Reviews The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Diversity of Human Immune System Multigene Families and its Implication in the Genetic Background of Rheumatic Diseases
Current Medicinal Chemistry Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine